The agreement provides Advanced Oncology Systems (AOS) with the rights to sell in most eastern European countries, with a primary focus in Hungary, Poland, Romania, Bulgaria, the Russian Federation, Ukraine and Georgia.
Sales will be consummated primarily through specialty distributors; however, in certain instances, direct to hospital sales are permitted. Minimum sales performance criteria for each product platform are stipulated in the agreement.
Michael McManus, Jr, president and CEO of Misonix, said: “Misonix is excited about AOS joining our sales and distribution organization. We are quite familiar with AOS’s past sales successes in central and eastern Europe. We are very pleased that they will be representing four of our product platforms to their well-established distribution channels.”